title: The public health benefit of medicines: how it has been assessed in France? The principles and results of five years' experience.
abstract: Health technology assessment seeks to inform health policy- and decision-makers by promoting use of current best evidence and by addressing country specific factors, such as local context and values. In France, public health benefit (PHB) is one of the criteria used to inform decisions on the reimbursement of medicines. This article describes the methodological framework and the results after five years of assessment of PHB, by the French National Authority for Health. The semi-quantitative method used includes three dimensions that are: (1) the ability of a drug to improve the population's health status, (2) the drug's adequacy to cover public health needs, and; (3) the impact of the drug on the healthcare system. From 2005 to 2010, the PHB of 530 drugs was estimated, and 72% were assessed as having no PHB. The PHB was "low" for 88% of drugs expected to have a PHB, "medium" for 10%, and was considered to be "high" in only one case. The results of this experience show that it is feasible to assess the public health impact of drugs. But the high level of uncertainties at the time of a drug's first appraisal limits the assessment, which obviously has to be completed by reappraisal with post-marketing studies.
authors.affiliation: Hôpital Henri Mondor, Assistance Publique-Hôpitaux de Paris, Université Paris-Est Créteil, INSERM U955, Créteil, France.
authors.forename: Patrick
authors.initials: P
authors.lastname: Maison
authors.forename: Laura
authors.initials: L
authors.lastname: Zanetti
authors.forename: Anne
authors.initials: A
authors.lastname: Solesse
authors.forename: Gilles
authors.initials: G
authors.lastname: Bouvenot
authors.forename: Jacques
authors.initials: J
authors.lastname: Massol
mesh_terms: D003362:Cost-Benefit Analysis; D003657:Decision Making; D004335:Drug and Narcotic Control; D055317:Evidence-Based Practice; D005602:France; D006305:Health Status Indicators; D006801:Humans; D017891:Pharmacoepidemiology; D055553:Prescription Drugs; D000091402:Prohibitins; D011634:Public Health; D013673:Technology Assessment, Biomedical
chemical_list: C000717328:PHB protein, human; D055553:Prescription Drugs; D000091402:Prohibitins
keywords: Drugs policy; Health technology assessment; Pharmaco-epidemiology; Public health